{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-130433","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.565902+00:00","generated_at":"2026-05-15T08:23:33.377497+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Viridian Therapeutics announces positive phase 3 topline results for elegrobart in active thyroid eye disease","bullets":["REVEAL-1 met primary endpoint with 54% proptosis responder rate for elegrobart Q4W vs 18% placebo at week 24 (p<0.0001).","Elegrobart Q8W achieved 63% proptosis responder rate vs 18% placebo at week 24.","Complete resolution of diplopia in 51% of Q4W patients vs 16% placebo at week 24.","BLA submission for elegrobart anticipated in Q1 2027; REVEAL-2 top-line data expected Q2 2026.","Company ended Q4 2025 with $875M cash; veligrotug PDUFA date June 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-130433","json":"https://secwatch.observer/filing/0001193125-26-130433.json","markdown":"https://secwatch.observer/filing/0001193125-26-130433.md","text":"https://secwatch.observer/filing/0001193125-26-130433.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/0001193125-26-130433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/d27955d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T08:23:33.377497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}